1

CURRICULUM VITAE

Dr. Pietro Ravani

I. BIOGRAPHICAL DATA

Name: Pietro Ravani

Address: C210N, Foothills Medical Centre 1403 - 29th Street NW, Calgary, AB T2N 2T9

Telephone: 403-944-8172 E-mail: pravani@ucalgary.ca

Present Rank: Associate Professor

Department: Medicine Division: Nephrology

Faculty: Medicine Institution: University of Calgary

II. ACADEMIC RECORD

Final Degree: PhD

Date completed: 2009-2011 Specialty: Doctor of Philosophy, Clinical Epidemiology Institution: Memorial University of Newfoundland, St John's, Canada

i Undergraduate

1989-2010 MD, University of Parma, Parma, Italy

ii. Special Professional

December 1991 Thesis "Recombinant Human Erythropoietin in Dialysis Patients" University of Parma, Internal Medicine, Nephrology-Medicine Degree, Cremona, Italy

October 1993

Thesis defence: October 12, 1993 50/50 with distinction: Defend thesis title "Pathophysiology of hepat-renal syndrome", University of Parma, Fellow, Nephrology- Nephrology Fellowship, General Internal Medicine Residency, Cremona,

Italy October 1993

University of Parma, Internal Medicine-Fellowship, Parma, Italy

2

April 2004 Thesis Defended Oct. 25, 2004. Title: "Variance corrected method for the analysis

of correlated time-to-event data", University of Pavia, Pavia, Italy, Master of Science, Biostatistics-Mathematics/Biostatistics, Pavia, Lombardy, Italy, Supervisor:

PF Mario Comelli January 2009

Thesis defense on Risk Estimation in Longitudinal Studies, Memorial University of Newfoundland, Doctor of Philosophy, Clinical Epidemiology-Clinical Epidemiology,

St. John's Newfoundland and Labrador, Canada, Supervisor: PF BJ Barrett, Supervisory committee: PS Parfrey, GMugford, BR Hemmelgarn

iii Graduate and Post-Doctoral

October 2004 MSc, Biostatistics, University of Pavia, Italy, Pavia, Lombardy, Italy

November 2009 PhD, Doctor of Philosophy, Clinical Epidemiology, Memorial University of

Newfoundland, St. John's, Newfoundland and Labrador, Canada

iv Licensure, Certification and Boards October 1989

Fellow, National College of Physicians and Surgeons of Italy, FNCPSI, General Medicine, University of Parma

September 2008- December 2008 Courtesy License , College of Physicians & Surgeons of Alberta (CPSA)

September 2009

Special License under Part 5 (AB) Landed immigrant status as of July, 2011, the University of Calgary, S11608

Member, Royal College of Physicians & Surgeons of Canada (The), 2003734

Member, College of Physicians & Surgeons of Alberta, S11608 Member, The Canadian Medical Protective Association (CMPA), 20079855

January 1993

Fellow, National College of Physicians & Surgeons, Italy, FNCPSI, Nephrology, University of Parma

3

III AWARDS AND DISTINCTIONS

2014 Teaching Excellence, UME, The University of Calgary, Instructor, UME

2013 Teaching Excellence, UME, The University of Calgary, Instructor, UME

2012

Distinguished Fellow of the European Renal Association, Fellow of the European Renal Association (FERA), Investigator

Department of Medicine Quality Improvement & Patient Safety Award, Alberta Health Services, Doctor

Teaching Excellence, UME, The University of Calgary, Instructor, UME

2011 Teaching Excellence, The University of Calgary, Instructor, UME

2010

Teaching Excellence, The University of Calgary, Instructor, UME 2009

Graduate Program Prize, Memorial University of Newfoundland, PhD student, $1,000

2005-2006-2007 Marie-Curie Actions, Outgoing International Fellowship #21676, Research title:

"Can it Prevent?", RCT for the prevention of contrast induced nephropathy, Memorial University of Newfoundland, PI, $130,000

2004 Grant for Research Excellence, Italian Society of Nephrology, Master of Biostatistics,

$7,500

Grant for Research Excellence, Italian Society of Nephrology, Doctor of Philosophy, $7,000

2003 Young Investigator Award, European Renal Association, Assistant Professor,

Universities of Pavia, $5,000

4

1989 Health Grant, Awarded to the winners of examinations entrance for admission to

the graduate school of Nephrology, Italian Ministry of Health, Fellowship Nephrology, $39,000

1985 Italian Blood Tour Association Grant, Medical exams passed with distinction,

University of Parma, Internal Medicine Residency

IV ACADEMIC APPOINTMENTS January 2009-Present

Associate Professor, The Libin Cardiovascular Institute of Alberta, The University of Calgary, Calgary, Alberta, Canada

Member, Abstract Selection Committee, International Society of Nephrology, Italy

Member, Scholarship Review Committee, Italian Society of Nephrology, Italy

Member, Abstract Selection Committee, European Renal Association, Italy

January 2008-Present Associate Professor of Medicine, Nephrology, Medicine, The University of Calgary, Calgary, Alberta Canada

Associate Professor, Community Health Sciences, The University of Calgary,

Calgary, Alberta, Canada Associate Professor, Medicine, The University of Calgary, Calgary, Alberta, Canada

January 2005-December 2006

Department of Pharmacy, Biostatistics, MUN fall semester, University of Pavia, Pavia, Lombardy, Italy

January 2002-December 2004 Department of Nephrology-Epidemiology, Medicine, University of Pavia, Pavia,

Lombardy, Italy January 2000-December 2008

Professor Contract-Part-time, Medicine-Nephrology, University of Pavia, Pavia, Lombardy, Italy

5

V EDUCATIONAL ACTIVITIES

i Undergraduate

January 2010-Present Small Group instruction on Journals, Tutorial, Seminar, Small Group, The University of Calgary

Committee Member, Dr. Lucia Di Micco-PhD, University of Naples, PhD Program-

Chronic Kidney Disease Committee Member, Dr. Tanvir Turin, post-doc PhD-University of Calgary,

Outcomes of Chronic Diseases

April 2012-June 2012 Course IV Topics included: Fluid & Edema; Hyponatremia; Hypernatremia; Hypertension I; Resistant Hypertention II; Abnormal Hydrogen Ion Concentration;

Acute Renal Failure; abnormal Urine Analysis; Chronic Kidney Disease I; Chronic Kidney Disease II; 2011-2012 Academic Year, Small Group Instruction, The

University of Calgary, Health Science Centre, HSC

January 2011-December 2011 Teaching Clinical Clerks while On Call, Clinical Skills Teaching, FMC, The University of Calgary, FMC

April 2011-May 2011 Course IV Topics: Fluid & Edema; Hypertension I; Resistant Hypertension II;

Abnormal Hydrogen Ion Concentration; Acute Renal Failure, Small Group Instruction, The University of Calgary, HSC

April 2010-May 2010 MED 440, Lecture, The University of Calgary

Academic Year, Small Group Instruction, The University of Calgary, HSC March 2009-March 2010

Monthly Service Clerk Bedside, Mentoring, The University of Calgary

Course IV Nephrology & Endocrinology. Subjects: Hyponatremia, Hypernatremia; Stephen Appleby II, Hypertension, Initial patient visit, Tutorial, Seminar, Small Group, The University of Calgary, HSC

Examination Committee Member, Dr. Michael Walsh, Clinical Epidemiology

Committee Member, Dr. Vinay Deved, Clinical Epidemiology

January 2012-December 2012 Mentor, Mr. Rameez Kabani, Medicine

Mentor, Ms. Puneep Kapur, Medicine

6

January 2012-Present Mentor, Ms. Sheila Garland, Psychology

January 2010-December 2011

Committee Member, Mr. Geoff Brin, Medical School, University of Calgary, Medicine January 2011-December 2011

Mentor, Mr. Bedi Harman, Kinesiology

January 2006-December 2008 Committee Member, Mr. Matteo Conca, Medicine

January 2005-Deember 2008 Committee Member, Ms. Elena Cremaschi, Medicine

ii GRADUATE (course and student supervision)

January 2010-Present

Teaching Clinical Skills for Urgent Clinic. Teaching Biostatistics, Teaching Research Methods, Clinical Skills Teaching, University of Calgary, Calgary, Alberta

Mentoring and advising to graduates and fellows.

PhD, MSc, Fellows-Jan., Feb., and March Mentoring, The University of Calgary-Academic, Calgary, Alberta

Monthly Service, Mentoring; The University of Calgary Committee Member, Dr. Lucia Di Micco-PhD, University of Naples, PhD Program-

Chronic Kidney Disease

Committee Member, Dr. Tanvir Turin, post-doc (PhD)-University of Calgary, Outcomes of Chronic Diseases.

October 2008 Lombardy Registry (Contrast Induced Nephropathy), Lecture, University of Brescia

Contrast Induced Nephropathy, Lecture, University of Bari

August 2005-August 2007 Clinical Epidemiology PhD Program (PF biostatistics), visiting Professorship,

Memorial University of Newfoundland Nephrology Rounds; (analytical methods for correlated data), Seminar, Rounds

Presented, University of Ottawa

Analytical methods for correlated data, Seminar, Rounds Presented, University of Calgary

7

January 2006-December 2006

Epi PhD, Concepts interaction, Seminar series

Epi PhD, Concept in causation, Seminar series Epi PhD, Extended Cox's models (seminar series), Tutorial, Seminar, Small Group,

University of Pavia

Epi PhD, Analysis of correlated data, Seminar series Epi PhD, Confounding and interaction, Seminar series

September 2005-December 2005 Epi PhD, Emerging CV risk factors (seminar series), Tutorial, Seminar, Small Group, University of Pavia

September 2004-December 2004

Clinical Epidemiology PhD Program (PF biostatistics), Visiting Professorship, Memorial University of Newfoundland

Epi PhD, Repeated event models, Seminar Series, University of Pavia

January 2011-December 2014 Committee Member, Dr. Melike Ozcan, Histopathology

Committee Member, Dr. Denny Ying, Histopathology Co-Supervisor, Dan Devoe, Health Sciences Supervisor, Dr. Kelvin Leung, MSc Health Sciences

Mentor, Mr. Barry Holowell, Medicine Mentor, Ms. Leila Barss, Psychology

Mentor, Dr. Brett Kilb, Medicine April 2009-March 2010

Monthly Service, Mentoring, The University of Calgary Examination Committee Member, Dr. Michael Walsh, Clinical Epidemiology.

Committee Member, Dr. Vinay Deved, Clinical Epidemiology surgery and pre-D care, Specialty Training in Nephrology

October 2008 Lombardy Registry (Contrast Induced Nephropathy), Lecture, University of Brescia

Contrast Induced Nephropathy, Lecture, University of Bari January 2007 - December 2008

Primary Supervisor, Dr. Andrea Pota, PhD student, training in biostatistics, University of Naples, PhD in Biostatistics.

8

January 2002 - December 2004 Primary Supervisor, Dr. Annalisa Foschi, Clinical Education, Nephrology fellow,

Specialty Training in Nephrology.

January 2000 - December 2004 Primary Supervisor, Dr. Paola Pecchini (research training), Master of Science, Biostatistics.

iii. Postgraduate (research and clinical fellows)

January 2012-Present Mentoring, The University of Calgary, Calgary Alberta

January 2012-December 2012

Mentoring Fellows, Specialty Training in Nephrology Supervising Fellows, Specialty Training in Nephrology

January 2011-December 2011 Teaching Nephrology Residents rotating through Nephrology while on call. 6

Residents until June, 2011, 4 Residents thereafter, Clinical Skills Teaching, Foothills Medical Centre, Calgary, Alberta.

Vasculitis Lecture to Fellows Class, Resident Lectures, The University of Calgary. Mentoring, Fellows, Specialty Training in Nephrology. Supervisor, Fellows, Specialty Training in Nephrology.

2010-Present

Monthly service-Fellows Bedside, Mentoring, The University of Calgary Fellows Class, Lecture, The University of Calgary.

January 2009-December 2009 Supervisor, Dr. M. Sarna and Dr. Kelvin Leung, 2 Acute Clinics each, Specialty

Training in Nephrology. April 2009-March 2010

Monthly Service-Fellows Bedside Mentoring. The University of Calgary. Fellows Classroom-Small Group Instruction, The University of Calgary.

iv. Continuing Medical Education

Grand Rounds and Research Rounds: Journal Clubs, Worshops/Seminars, The University of Calgary. (2012-Present)

Supervision and Mentoring of fellows and residents, The University of Calgary. (2012-Present)

Clinical advising and Mentoring to residents and fellows, The University of Calgary.

(2012-Present)

9

Abnormal Serum Potassium, Lecture. (2014)

Abnormal Hydrogen Ion Concentration, Lecture. (2014)

Fluid and Edema, Lecture. (2014) Hyponatremia, Lecture (2014)

Hypernatremia, Lecture (2014)

Hypertension 1, Lecture (2014)

Resistant Hypertension 2, Lecture (2014)

Teaching Methodology JC, Lecture ,University of Calgary (2014) Chronic Kidney Disease, Lecture, University of Calgary (2013)

SIN Presentation, Lecture, University of Calgary (2013)

Journal Club Mentoring, University of Calgary (2010)

Italian Soc Nephrology, Introduction to epidemiology, Lecture, University of Milan, Milan. (2005)

Italian Soc Nephrology, Introduction to biostatistics, Lecture, University of Milan,

Milan. (2004) v. Community Education

Supervising and mentoring for workshops, Education Material Development. (2010)

The diabetes and the Kidney, Education Material Development, University of Cremona, Italy, Palazzo del Comune. (2001)

Diagnosis and treatment of hypertension, Education Material Development, Cremona, Italy. (1998)

VI. ADMINISTRATIVE RESPONSIBILITIES

i. Faculty/University: 2011 Member, Selection Committee, Statistical Analysts, Research

Projects-The University of Calgary. 2010-Present Member, Residency Training Committee (RTC)-research - The

University of Calgary.

2009-2012 Member, U of C Health Investigator Group - The University of Calgary.

10

ii. Hospital

2011-Present Member Renal Rehabilitation Committee-Rocky view General Hospital .

Member Steering Committee, The Health Improvement Network (THIN), Foothills Medical Centre/University of Calgary, Medicine, Division of Nephrology.

2008-Present Member of the Medical Staff as a Nephrologist, Foothills Medical Centre, Peter Lougheed Centre, Rocky view General Hospital,

Alberta Health Services, Medicine, Division of Nephrology. 2011 Member Renal Bio bank Committee, FMC/University of Calgary, Medicine.

1992-2008 Nephrology, Lombardy Region, Medicine

iii. Regional Health Authority 2011-Present Member Kidney Bio bank-Alberta Health Services. 2011-Present Co-Director, Vascular Access Program-Vascular Access Clinic.

2008-Present Member SARP Vascular Access Clinical- Foothills Medical Centre.

iv. Provincial or Territorial 2011-Present Member The Health Improvement Network (THIN) Steering

Committee-University of Calgary. 2010-Present Participant, AKDN-Alberta Kidney Disease Network. Member ICDC Research Committee-Interdisciplinary Chronic

Disease Collaboration. 2008-Present Member SARP Vascular Access Team, Division of Nephrology.

2000-2008 Director, Hemodialysis Service, Italy Director, CKD, Italy

VII. PROFESSIONAL ACTIVITIES

i. Membership in professional and learned societies

2011-Present Abstract Selection Committee International Society of Nephrology.

2010-Present Membership in professional and learned societies, Canadian Society of Nephrology. Membership in professional and learned societies, International

Society of Nephrology .

2009-Present Professional Service, EU Registry of Dialysis and Transplantation, ERA-EDTA Scientific Committee Member, EU Registry of Dialysis and

Transplantation, ERA-EDTA.

2007-Present Associate Editor - Statistical Editor, Editorial Board: Journal of Nephrology.

11

2006 Member/ Grant Review Committee, Zon Mw, The Nederland Organization for Health Research and Development.

2005-2006 Member Editorial Board: Giornale Italiano di Nefrologia.

2005 Vascular Access Chair, European Renal Association-Abstract Selection Committee.

Member Italian Society of Nephrology: Abstract Selection Committee.

Provincial Service, Italian Registry of Dialysis and Transplantation. Member Scholarship Review Committee, Italian Society of

Nephrology. Member National Scientific Committee, Italian Society of

Nephrology. 2003 Member American Society of Nephrology.

1999 Member Italian Society of Nephrology

1991 Member European Renal Association

ii. Professional Service

Grant Panels

2011-Present Kidney Foundation of Canada, Member Scientific Committee.

2009-Present Canadian Institutes of Health Research (CIHR) Member.

Grant Review 2010-Present Peer review of Grants for FMC Division of Nephrology,

Community of Health Sciences.

Journal Reviews 2011 World Congress, Chair of Vascular Access: Review of Journals,

Journal of Nephrology, Journal of the American Society of Nephrology, Nephrology Dialysis and Transplantation.

2010-Present The Kidney Foundation of Canada (KFOC) Member: Journal Reviews.

Scientific Committee of Vascular Access, Scientific Committee of Vascular Access Journal Review.

12

2009-Present Journal review -American Journal of Kidney Disease. American Society of Nephrology, Journal Review-Clinical Journal

of the American Society of Nephrology. Editorships

2009-Present Italian Society of Nephrology, Co-editor, Giornale Italiano de Nefrologia. 2009 Co-editor, Journal of Nephrology.

National and International Committees

2012-Present Member CHEP-Canadian Hypertension Education Program. Member Review Committee-The Kidney Foundation of Canada. Member Practise Guideline Committee-Canadian Society of

Nephrology. Member Practise Guideline Committee-Italian Society of

Nephrology. 2011-Present Member CIHR Transplant Initiatives-Canadian Institute of Health Research.

2009-Present Member Scientific Committee European Registry -ERA-EDTA. 2007 Chair ERA-EDTA, Scientific Committees, Section Chair- ERA-

EDTA, European Renal Association. 2005 Member National Meetings and Education Event Program-Italian

Society of Nephrology. 2005-2011 Member Canadian Investigator Group. 2005-2010 Member National Registry of renal replacement therapies,

scientific committee member-Italian Society of Nephrology.

VIII. RESEARCH SUPPORT 2011/01 - 2016/12 $17,500,000, Funded, Team Member, Canadian Network for

Observational Drug Effect Study (cNODES), CIHR

2012/01 - 2014/12 $100,000, Funded, Co-PI, Reducing the risk of serious

adverse events and improving the quality of life for patients

with kidney disease: the role of arteriovenous fistula crea+ons

in hemodialysis patients, AFMR

2012/01 - 2014/12 $96,000, Funded, Co-PI, Reducing the risk of serious adverse

events and improving the quality of life for patients with

kidney disease: the role of arteriovenous fistula crea+ons in

hemodialysis patients, MSI

2009/01 - 2014/12 $5,000,492, Funded, Co-investigator, Improving the Efficient

and Equitable Care of Patients with Chronic Medical

Conditions: The Interdisciplinary Chronic disease

Collaboration (ICDC), Alberta Innovates Health Solutions

(formerly Alberta Heritage Foundation for Medical Research)

13

2012/07 - 2014/07 $100,000, Funded, Co-PI, Reducing the risk of serious

adverse events and improving the quality of life for patients

with kidney disease: the role of arteriovenous fistula creations

in hemodialysis patients, Ashford AFMR

2011 - 2013 $165,000, Funded, Co-investigator, Emerging Research Team

Grant Program: “Biomarkers of Viral Pathogenesis”, The

University of Calgary and Alberta Health Services

2013/01 - 2013/12 $18,000, Funded, Principal/Senior investigator, Outcomes of

patients transitioning from transplant to dialysis, University of

Calgary

2013/01 - 2013/12 $9,000, Funded, Principal/Senior investigator, Risk of cancer

in patients transitioning from transplant to dialysis, Private

donor

2011/01 - 2013/12 $166,448, Funded, Co-investigator, Improving Risk Prediction

for Mortality and Progression to Kidney Failure in Older Adults

Using eGFR and Proteinuria. Co-applicant with Brenda

Hemmelgarn, Canadian Institutes of Health Research (CIHR)

2011/01 - 2013/12 $148,998, Funded, Principal/Senior investigator,

Complications of Arteriovenous Fistulas, Arteriovenous Grafts

and Tunnelled Cuffed Catheters for Hemodialysis: Risk

Patterns, Comparability and Impact on Patient Outcomes,

CIHR

2011/01 - 2013/12 $166,448, Funded, Co-investigator, Improving risk prediction

for mortality and progression to kidney failure in older adults

using eGFR and proteinuria, CIHR

2009/01 - 2013/12 $3,319,686, Funded, Co-investigator, The BK:KIDNI Trial

(BK:Kinase Inhibition to Decrease Nephropathy Intervention

Trial), CIHR

2011 - 2012 $20,000, Funded, Principal/Senior investigator, Vascular

Access Teams in Alberta, The University of Calgary

2012/01 - 2012/12 $5,000, Funded, Principal/Senior investigator,

Immunosuppressive strategies and outcomes of patients

transitioning from transplant to dialysis: systematic review,

AIHS

2011/07 - 2012/06 $182,683, Funded, Principal/Senior investigator, Promoting

the arteriovenous fistula as hemodialysis access: expected

benefits and unintended consequences, Canadian Institutes of

Health Research (CIHR)

14

2010/01 - 2011/12 $10,000, Funded, Principal/Senior investigator, Analytical

methods for the analysis of the vascular access survival data,

University of Calgary

2010/01 - 2011/12 $50,000, Funded, Co-investigator, Elucidating the clinical

relevance of mRNA in diffuse large B cell lymphomas, AB

Cancer Foundation

2006/01 - 2007/12 $140,000, Funded, Principal/Senior investigator, Can-It Prevent? RCT for the prevention of contrast induced nephropathy

Total Grant: 90,000 Euros, European Union

2005/01 - 2005/12 $45,000, Funded, Principal/Senior investigator, Analytical

Methods for multiple survival times

Total Grant amount: 30,000 Euros, Italian Society of

Nephrology

2004/01 - 2004/12 $8,000, Funded, Principal/Senior investigator, Short term

outcomes of the arteriovenous fistula for hemodialysis

Co-Investigators: Favio Malberti, Brendan Barrett

Total Grant: 5,000 Euros, Italian Soc. Nephrology

2003/01 - 2003/12 $3,000, Funded, Principal/Senior investigator, Cardiovascular

disease and late referral impact fistula outcomes

Total Grant 2000 Euros, EDTA-ERA

IX. INVITED ADDRESSES/PRESENTATIONS

I. Invited Addresses

1. Invited Speaker, " The ACCeSS Trial", City Wide Renal Rounds,

Calgary,Alberta, Canada , November 20th, 2014.

2. Invited Speaker, "Calcimimetics for secondary hyperparathyroidism in

CKD:meta-analysis of RCT's", Catania, Italy, October 10th, 2014.

3. Invited Speaker, "Use of computerized data for Health Services Research",

Catania, Italy, October 9th, 2014.

4. Invited Speaker, "Mortality following kidney allograft failure", ICDC/AKDN

Research Rounds, Calgary, Alberta, Canada, February 13, 2014

5. Invited Speaker, Italian Society of Nephrology L'accesso vascolare (vascular

access), SIN Meeting for fellows, Italy, 2014

6. Invited Speaker, Infectious and non-infectious complications of the

hemodialysis access, CSN, Vancouver, British Columbia, Canada, 2014

7. Invited Speaker, Making Risky Transition Safer, Memorial University of

Newfoundland and Labrador, Canada, 2014

15

8. Invited Speaker, "Making risky transitions safer”, City Wide Renal Rounds,

Calgary, Alberta, Canada December 2013

9. Invited Speaker, “Outcomes of people with kidney allograft failure”, ALTRA

Rounds, Calgary, Alberta, Canada October 2013

10. Invited Speaker, “Recommendations for Laboratory Screening in

Hypertension”, CHEP, Montreal, Quebec, Canada October 2013

11. Invited Speaker, (Italy): “Use of Rituximab in Juvenile Nephrotic Syndrome”,

Italy, Catania, Sicilia, Italy September 2013

12. Presenter, Euro-DOPPS, Amstradam, Netherlands. March 2013

Invited Speaker, MUN Lecture: Competing Risks, MUN, Calgary, Alberta,

Canada, March 2013

13. Presenter, Use of Rituximab in Nephrology, University of Calgary, Calgary,

Alberta, Canada, February 2013

14. Invited Speaker, The temporal profile of the risks for infectious and non-

infectious complications of the vascular access for hemodialysis: results from

DOPPS’, American Society of Nephrology, San Diego, California, United

States, October 2012

15. Invited Speaker, Association between type of hemodialysis access and clinical

outcomes: Meta-analysis of cohort studies, American Society of Nephrology,

San Diego, California, United States, October 2012

16. Invited Speaker, CHEP (Canadian Hypertension Education Program); theme

“Renal denervation”, CHEP, Alberta, Canada, October 2012

17. Invited Speaker, CHEP (Canadian Hypertension Education Program);

“Treating Hypertension i the Elderly”, CHEP, Alberta, Canada, October 2012

18. Invited Speaker, Advances in preparation and management of vascular

access for hemodialysis, Diaverum, Catania, Sicily, Italy, October 2012

19. Invited Speaker, Vascular Access in Europe, San Diego, California, United

States, March 2012

20. Invited Speaker, Metanalysis of Vascular Access and Patient Outcomes,

ICDC/AKDN Research Rounds, Calgary, Alberta, Canada, January 2012

21. Invited Speaker, Renal Care Programs in Canada, Italian Society of

Nephrology, Annual Meeting, Genoa, Liguria, Italy, September 2011

22. Invited Speaker, Nephrology Next Generation: Renal Care Programs, Italian

Society of Nephrology, Italy, April 2010

23. Invited Speaker, Do we really need an RCT to prove which vascular access is

best for hemodialysis, University of Calgary, Calgary, Alberta, Canada, March

2010

16

24. Invited Speaker, MUN Lecture on Risk Estimation in Longitudinal studies,

University of Newfoundland, Canada, November 2009

25. Invited Speaker, Annual Meeting of the Italian Society of Nephrology, Italian

Society of Nephrology, Italy, October 2009

26. Invited Speaker, Annual Meeting of the Canadian Society of Nephrology at

the ASN, ASN, San Diego, California, United States, October 2009

27. Invited Speaker, Nephrology Rounds-Contrast Nephropathy, University of

Calgary, Calgary, Alberta, Canada, June 2009

28. Plenary Keynote Speaker, Italian Society of Nephrology (II Scientific fair),

Italian Society of Nephrology, Italy, March 2009

29. Invited Speaker, Italian Society of Nephrology (II Scientific fair), Italian

Society of Nephrology (II Scientific fair), Italy, March 2009

30. Invited Speaker, Lombardy Registry- Contrast-Induced Nephropathy,

University of Brescia, Brescia, Lombardy, Italy, October 2008

31. Invited Speaker, Contrast Induced Nephropathy, Italian Society of

Nephrology, Bari, Bari, Italy, June 2008

32. Invited Speaker, Italian Society of Nephrology (I Scientific fair), Italy, March

2008

33. Invited Speaker, La gravidanza nelle donne con insufficienza renale cronica

moderata e severa: fattori predittivi del rischio materno e fetale; sin meeting

Bari 2007, Italian Society of Nephrology, Italian Society of Nephrology, Bari,

Bari, Italy, October 2007

34. Invited Speaker, Analytical Methods for correlated data, University of Ottawa,

Ottawa, Ontario, Canada, June 2007

35. Invited Speaker, Analytical Methods for correlated data, University of

Calgary, Alberta, Canada, June 2007

36. Invited Speaker,

http://www.asdin.org/Visitors/PDFS/ASDIN_FinalBrochureSinglePages.pdf,

American Society of Diagnostic & Interventional Nephrologists (ASIDN), Rio

Grande, San Juan-Caguas-Guaynabo Metropolitan Statistical Area, Puerto

Rico, April 2007

37. Invited Speaker, Mechanisms of Arteriovenous Access Failure:

http://www.britishrenal.org/conferences/brs2006/programwed.shtml, British

Renal Soc(BRS)/Renal Assocation Integrated Meeting, Harrowgate, North

Yorkshire, England, United Kingdom, May 2006

38. Invited Speaker, Multidisciplinary Clinic and Dialysis Outcomes: the Barrier of

Late Patient Referral. Perit Dial Int 25 (suppl. 5): S30, 2005, Italian Society

of Nephrology, Italy, May 2005

17

39. Invited Speaker, Risultati a breve termine del primo accesso vascolare (AVF):

studio multicentrico. G Ital Nefrol: s90, A343, ASN, Italy, November 2003

40. Invited Speaker, Longer maturation time improves arteriovenous fistula

survival: A prospective multi-center study, Nephrol Dial Transplant:732A,

ERA-EDTA, 2003, Berlin, Germany, June 2003

41. Invited Speaker, How the Pre-D Educational Program impacts clinical

outcomes after dialysis start, Baxter Symposium, EDTNA Meeting, The

Hague, Netherlands, 2002

42. Invited Speaker, Contrast Induced Nephropathy, University of Brescia;

Lombardy Registry,

ii. Presentations

1. Invited Speaker, "Rituximab in Children with Nephrotic Syndrome" for Renal

Grand Rounds, Department of Medicine, Division of Nephrology, Calgary,

Alberta, Canada, June 2011

2. Visiting Professor, Seminar on Biostatistics for the PhD class in Clinical

Epidemiology, Memorial University of Newfoundland, St. John's

Newfoundland and Labrador, Canada, March 2011

X. PUBLICATIONS

i. Peer Reviewed Manuscripts

Year 2014

1. Nesrallah GE, Mustafa RA, Clark WF, Bass A, Barnieh L, Hemmelgarn BR,

Klarenbach S, Quinn RR, Hiremath S, Ravani P, Sood MM, Moist LM:

Canadian Society of Nephrology 2014 Clinical Practice Guideline for timing

the Initiation of Chronic Dialysis. CMAJ: 2014 Feb; 186(2):112-7. Doi:

10.1503/cmaj.130363.

2. Quinn RR, Ravani P, Zhang X, Garg AX, Blake PG, Austin PC, Zacharias JM,

Johnson JF, Pandeya S, Verelli M, Oliver MJ: Impact of Modality Choice on

rates of Hospitalization in Patients eligible for both Peritoneal Dialysis and

Hemodialysis. Perit Dial INT. 2014 Jan;34(1):41-8.

Doi:10.3747/pdi.2012.00257.

3. Esposito E, Ravani P, Mariani P, Huang N, Boldrini P, Drechsler M, Valacchi

G, Cortesi R, Puglia C.: Effect of Nanostructured Lipid Vehicles on

Percutaneous Absorption of Curcumin. Eur J Pharm Biopharm. 2014

Feb;86(2):121-32.

4. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Caskey F, Collart F,

Finne P, Fogarty DG, Groothoff JW, Hoitsma A, Nogier MB, Postorino M,

Ravani P, Zurriaga O, Jager KJ, Gansevoort RT; on behalf of the ERA-EDTA

18

Registry;EuroCYST Consortium; the WGIKD. Analysis of data from the ERA-

EDTA Registry Indicates that Conventional Treatments for Chronic Kidney

Disease do not Reduce the need for Renal Replacement Therapy in

Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2014 May 14

doi:10.1038/ki.2014.120.

5. Bruschi M, Sinico RA, Moroni G, Pratesi F, Migliorini P, Galetti M, Murtas C,

Tincani A, Madaio M, Radice A, Franceschini F, Tardanico R, Scaloni A,

D'Ambrosio C, Carnevali ML, Messa P, Ravani P, Barbano G, Bianco B,

Bonanni A, Scolari F, Martini A, Candiano G, Allegri L, Ghiggeri GM.

Glomerular Autoimmune Multicomponents of Human Lupus Nephritis in

Vivo:a-Enolase and Annexin A1.; J Am Soc Nephrol. 2014 May 1.

6. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS,

Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ,

Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos

G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G,

Gelfer M, Vallee M, Prasad GV, Lebel M, McLean d, Arnold JM, Moe GW,

Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilivie RI, Woo

V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA,

Drouin D, Lavoie KL, Lamarre-Cliche M, Tremblay G, Hamet P, Fodor G,

Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner

SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M,

Reid DJ, Tobe SW, Padwal RS, Poirier L; Canadian Hypertension Education

Program. The 2014 Canadian Hypertension Education Program

Recommendations for Blood Pressure Measurement, Diagnosis, Assessment o

f Risk, Prevention and Treatment of Hypertension. Can J Cardiol. 2014

May;30(5):485-501.

7. Ricci G, Canducci E, Guida A, Frascari A, Rossi A, Bersani G, Ravani P, Alvisi

V. The Gender-related differences of Nurtirent Intakes in a group of Italian

Obese Patients display the ongoing Transition from Mediterranean to Western

Dietary Patterns. Obes Surg. 2014 Jun;24(6):965-7.

8. Manns BJ, Scott-Douglas N, Tonelli M, Ravani P, LeBlanc M, Dorval M,

Holden R, Moist L, Lok C, Zimmerman D, Au F, Hemmelgarn BR.

An Economic Evaluation of rt-PA Locking Solution in Dialysis Catheters. J Am

Soc Nephrol. 2014 Jul 10: pii: ASN;2013050463.

9. Kabani R, Quinn RR, Palmer S, Lewin AM, Yilmaz S, Tibbles LA, Lorenzetti DL,

Strippoli GF, McLaughlin K, Ravani P; Alberta Kidney Disease Network. Risk

of death following Kidney Allograft Failure: A Systematic Review and Meta-

Analysis of Cohort Studies. Nephrol Dial Transplant. 2014 Sep;29 (9):1778-

86. doi:10.1093/ndt/gfu205.

10. Wuhl E, Van Stralen KHJ, Wanner C, Ariceta G, Heaf JF, Bjerre AK, Palsson R,

Duneau G, Hoitsma AJ, Ravani P, Schaefer F, Jager KJ. Renal Replacement

Therapy for Rare Diseases affecting the Kidney: An Analysis of the ERA-EDTA

19

Registry. Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv 1-8. Doi:

10.1093/ndt/gfu030.

11. Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, Areste N,

de la Torre RA, Caskey F, Couchoud C, Finne P, Heaf J, Hoitsma A, de

Meester J, Pascual J, Postorino M, Ravani P, Zurriaga O, Jager KJ,

Gansevoort RT;ERA-EDTA Registry; EuroCYST Consortium; WGIKD. Renal

Replacement Therapy for Autosomal Dominant Polycystic Kidney Disease

(ADPKD) in Europe: Prevalence and Survival--an Analysis of Data from the

ERA-EDTA Registry. Nephrol Dial Transplant. 2014. Sep;29 Suppl 4:iv15-25.

Doi: 10.1093/ndt/gfu017.

12. Pastormerlo LE, Ciardetti M, Trianni G, Ravani P, Shlueter M, Vaghetti M,

Coceani M, Rizza A, Berti S, Palmieri C. Drug Eluting Balloon: A Multipurpose

Tool for Coronary Revascularization With Optimal Long-Term Follow-Up

Results. J Interv Cardiol. 2014 Sep 9. Doi:10.1111/joic.12154.

13. Marsella M, Salvagno G, Dolcini B, Ferlini A, Ravani P, Harteveld CL,

Giordano PC, Borgna-Pignatti C. Characterization of Hb Calvino

(HBB:c.406G>A): A New Silent B-Globin Gene Variant Found in Coexistence

with a-Thalassemia in a Family of African Origin. Hemoglobin.

2014:38(5):369-72. Doi:10.3109/03630269.2014.948186.

14. Veglia F, Amato M, Govannardi M, Ravani P, Tedesco CC, Frigerio B,

Sansaro D, Tremoli E, Baldassarre D. Potentially Spurious Correlations

Between Arterial Size, Flow-Medicated Dilation, and Shear Rate.

Hypertension. 2014 Sep 22. Pii:Hypertensionaha.114.03608.

15. Ferraro L, Beggiato S, Borroto-Escuela DO, Ravani P, O'Connor WT,

Tomasini MC, Borelli AC, Agnati LF, Antonelli T, Tanganelli S, Fuxe K.

Neurotensin NTS1-Dopanine D2 Receptor-Receptor Interactions in Putative

Receptor Heteromers: Relevance for Parkinson's Disease and Schizophrenia.

Curr Protein Pept Sci. 2014;15(7):681-90.

16. Gualandi F, Bigoni S, Melchiorri L, Buldrini B, Balboni A, Neri M, Armaroli A,

Parmeggiani G, Italyankina E, Mauro A, Ravani P, Fini S, Caracciolo S,

Ferlini A.

Genetic Counseling for Women Referred for Advanced Maternal Age: A

Telegenetic Approach. Genet Med. 2014 Oct;16(10):795. Doi:

10.1038/gim.2014.103.

17. Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata

S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF,

Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A,

Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P,

Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante

M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C,

Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S,

Chicca S, Galliani M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M,

20

Maixnerova D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha

K, Paczek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk

K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger

M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N,

Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton

RP, Gharavi AG. Discovery of New Risk Loci for IgA Nephropathy Implicates

Genes Involved in Immunity against Intestianl Pathogens. Nat Genet 2014

Oct 12. Doi: 10.1038/ng.3118.

18. Ravani P, Werba JP, Frigerio B, Sansaro D, Amato M, Tremoli E, Baldassarre

D. Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in

Primary and Secondary Cardiovascular Prevention. Curr Pharm Des. 2014

Oct 13.

Year 2013

19. Quinn RR, Ravani P, Fistula first and catheter last:fading certainties and

growing doubts. Nephrol Dial Transplant. 2013.

20. McBrien KA, Manns BJ, Chui B, Klarenbach SW, Rabi D, Ravani P,

Hemmelgarn BR, Wieb N, AuF, Cleent F. Health care costs in people with

Diabetes and their Association with Glycemic Control and Kidney Function.

Diabetic Care. 2013;36(5) 1172-80.

21. Wong BC, Ravani P, Manns BJ, Lewin A, Zhang X, Chin R, Hemmelgarn BR,

Tonelli M, Oliver MJ, Quinn RR. Association of a change in Erythropoiesis-

stimulating agent dose during Hospitalization and Subsequent Hemoglobin

Levels and Transfusions in Hemodialysis Patients. Am J Kidney Dis.

2013;62(5):947-52.

22. Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M,

Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini

A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A,

Scolari F, Reiser J, Ghiggeri GM. Rituximab is a Safe and Effective Long Term

Treatment for Children with Steroid and Calcineurin Inhibitor Dependent

Idiopathic Nephritic Syndrome. Kidney Int. 2013;84(5):1025-33.

23. Di Micco L, Quinn RR, Ronksley PE, Bellizzi V, Lewin A, Cianciaruso B, Ravani

P. Alberta Kidney Disease Network (AKDN). Urine Creatinine Excretion and

Clinical Outcomes in CKD. Clin J Am Soc Nephrol. 2013;8(11):1877-83.

24. Khan NA, Herman RJ, Quinn RR, Rabkin SW, Ravani P, Tobe SW, Feldman

RD, Wijeysundera HC, Padwal RS, Canadian Hypertension Education Program

Renal Denervation Therapy for the Treatment of Resistant Hypertension: A

Position Statement by the Canadian Hypertension Education Program. :Can J

Cardiol.2013.

25. Ronksley PE, Ravani P, Sanmartin C, Quan H, Manns BJ, Tonelli M,

Hemmelgarn BR. Patterns of Engagement with the Health Care System and

Risk of Subsequent Hospitalization Amongst Patients with Diabetes. BMC

Health Services Research. 2013;13: 399.

21

26. Ravani P, Gillespie BW, Quinn RR, MacRae J, Manns BJ, Mendelssohn D,

Tonelli M, Hemmelgarn BR, James M, Pannu N, Robinson BM, Zhang X, Pisoni

R. Temporal Risk Profile for Infectious and non-Infectious Complications of

Hemodialysis Access. J Am Soc Nephrol. 2013;24(10) 1668-1677.

27. Turin TC, James M, Ravani P, Tonelli M, Manns BJ, Quinn RR, Jun M,

Klarenbach S, Hemmelgarn BR. Proteinuria and Rate of Change in Kidney

Function in a Community Based Population. J Am Soc Nephrol. 2013;24(10):

1661-7.

28. Chin-Lenn L, Mack LA, Temple W, Cherniak W, Quinn RR, Ravani P, Lewin

AM, Quan ML. Predictors of Treatment and Mastectomy, Use of Sentinel

Lymph Node Biopsy and Upstaging to Invasive Cancer in Patiens Diagnosed

with Breast Ductal Carcinoma IN situ (DCIS) on Core Biopsy. Ann Surg

Oncol. 2013

29. Ravani P, Maas R, Malberti F, Pecchini P, Mieth M, Quinn RR, Tripepi G,

Mallamaci F, Zoccali C. Homoarginine and Mortality in pre dialysis Chronic

Kidney Disease (CKD) patients. PLoS One 2013:8(9):e72694.

30. Ravani P, Barrett BJ. Galectin 3 and new onset CKD:marker or mediator? J

Am Soc Nephrol. 2013;24(9): 1342-4.

31. Schroijen MA, van de Luijtgaarden MW, Noordzij M, Ravani P, Jarraya F,

Collart F, Prutz KG, Fogarty DG, Leivestad T, Prischl FC, Wanner C, Dekker

FW, Jager KJ, Dekkers OM. Survival in dialysis patients is different between

patients with diabetes as primary renal disease and patients with diabetes as

a co morbid condition. Diabetologia 2013;56(9):1949-57.

32. Faruque LI, Hemmelgarn BR, Wiebe N, Manns BJ, Ravani P, Klarenbach S,

Pelletier R, Tonelli M. Alberta Kidney Disease Network. Factors Associated

with Initiation of Chronic Renal Replacement Therapy for Patients with Kidney

Failure. Clin J Am Soc Nephrol 2013;8(8):1327-35.

33. Thompson S, Bello A, Wiebe N, Manns BJ, Ravani P, Hemmelgarn BR,

Klarenbach S, Pelletier R, Tonelli M. Alberta Kidney Disease Network. Quality

of Care Indicators Among remote Dwelling Hemodialysis Patients:a cohort

study. Am J Kidney DIS. 2013;62(2):295-303.

34. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare

GF, Ravani P, Ernst P, Dormuth CR. The CNODES Investigators. Pronton

Pump Inhibitors and the Risk of Hospitalisation for Community Acquired

Pneumonia: Replicated Cohort Studies with Meta-analysis. Gut. 3013

35. Hackam DF, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Duskalopoulou SS,

Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE,

Ruzicka M, Mckay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P,

Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallee M,

Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger

JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J,

Trudeau L, Prettella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-

22

Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG,

Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA,

McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS; Canadian

Hypertension Education Program. The 2013 Canadian Hypertension

Education Program Recommendations for Blood Pressure Measurement,

Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Can J Cardiol. 2013 May;29(5):528-42.

36. Elliott MJ, James MT, Quinn RR, Ravani P, Tonelli M, Palacios-Derflingher L,

Tan Z, Manns BJ, Kline GA, Ronksley PE, Hemmelgarn BR. Estimated GFR

and Fracture Risk; A Population Based Study. Clin J Am SOC Nephrol. 2013

May 9

37. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James M, Hemmelgarn

BR. Proteinuria and life expectancy. Am J Kidney DIS. 2013;61(4):(646-8)

38. Tai DJ, Conley J, Ravani P, Hemmelgarn BR, MacRae JM. Hemodialysis

prescription education decreases intradialytic hypotension. J Nephrol.

2013;26(2):315-22.

39. Ronksley PE, Sanmartin C, Quan H, Ravani P, Tonelli M, Manns B,

Hemmelgarn BR. Association between perceived unmet health care needs

and risk of adverse health outcomes among patients with chronic medical

conditions. Open Med. 2013 Feb 26;7(1):e21-30.

40. Ravani P, Palmer SC, Oliver MJ, Quinn RR, MacRae JM, Tai DJ, Pannu NI,

Thomas C, Hemmelgarn BR, Craig JC, Manns BJ, Tonelli M, Strippoli GF,

James MT. Associations between hemodialysis access type and clinical

outcomes: a systematic review. J Am Soc Nephrol. 2013 Feb 24(3):465-73.

41. Withl E, Van Stralen KJ, Verrina E, Bjerre A, Wanner C, Heaf JG, Zurriaga O,

Hoitsma A, Niaudet P, Palsson R, Ravani P, Jager KJ, Schaefer F. Timing

and outcome of renal replacement therapy in patients with congenital

malformations of the kidney and urinary tract. Clin J Am Soc Nephrol.

2013;8(1):67-74.

42. Palmer SC, Di Micco L, Razavian M, Craig JC, Ravani P, Perkovic V, Tognoni

G, Graziano G, Jardine M, Pellegrini F, Nicolucci A, Webster A, Strippoli GF.

Anti-platelet therapy to prevent hemodialysis vascular access

failure:systematic review and meta analysis. M J Kidney Dis.

2013;61(1):112-22.

Year 2012

43. Kramer A, Jager KJ, Fogarty DG, Ravani P, Finne P, Perez-Panades J, Prutz

KF, Arias M, Heaf JG, Wanner C, Stel VS. Association between pre transplant

dialysis modality and patient and graft survival after kidney transplantation.

Nephrol Dial Transplant. 2012 Dec 27(12):4473-80.

44. Temme J, Kramer A, Jager KJ, Lange K, Peters F, Miller GA, Kramar R, Heaf

JF, Finne P, Palsson R, Reisaeter AV, Hoitsma AJ, Metcalfe W, Postorino M,

Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, Gross O.

23

Outcomes of Male Patients with Alport Syndrome Undergoing Renal

Replacement Therapy. Clin J Am Soc Nephrol. September 20, 2012.

45. Ocak G, Van Stralen KJ, Rosendaal FR, Verduijn M, Ravani P, Palsson R,

Leivestad T, Hoitsma AJ, Ferrer-Alamar M, Finne P, De Meester J, Wanner C,

Dekker FW, Jager KJ. Mortality due to pulmonary embolism, myocardial

infarction, and stroke among incident dialysis patients. J Thromb Haemost.

September 12, 2012.

46. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James MT, Hemmelgarn

BR. Lifetime risk of ESRD. J Am Soc NEPHROL. 2012 Sept.23(9):(1569-78).

47. Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A, Bruno

F, Radice A, Furci L, Argentiero L, Carnevali ML, Messa P, Scolari F, Sinico

RA, Gesualdo L, Fervenza FC, Allegri L, Ravani P, Ghiggeri GM. Coexistence

of Different Circulating Anti Podocyte Antibodies in Membranous

Nephropathy. 2012 Sept. 7(9):(1394-400) Epub 2012 July 5.

48. Hemmelgarn BR, James MT, Manns BJ, O'Hare AM, Muntner P, Ravani P,

Quinn RR, Turin TC, Tan Z, Tonelli M. Alberta Kidney Disease Network:Rates

of treated and untreated kidney failure in older vs younger adults.

JAMA.2012 Jun 20;307(23):2507-15.

49. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E,

Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M,

Scolari F, Ghiggeri GM. Rituximab in Children with Resistant Idiopathic

Nephrotic Syndrome. J Am Soc Nephrol 23(6):1117-1124, 2012, Jun A.M.

and P.R. contributed equally to the work. Epub ahead of print June 7, 2012.

50. Stel VS, Kramar R, Leivestad T, Hoitsma AJ, Metcalfe W, Smits JM, Ravani

P, Jager KJ. Time trend in access to the waiting list and renal

transplantation: acomparison of four European countries. Nephrol Dial

Transplant. May 22, 2012.

51. Kramer A, Satel VS, Geskus RB, Tizard EJ, Verrina E, Schaefer F, Heaf JG,

Kramar R, Krischock L, Leivestad T, Paisson R, Ravani P, Jager KJ. The

effect of timing of the first kidney transplantation on survival in children

initiating renal replacement therapy. Nephrol Dial Transplant. 2012

Mar.27(3):1256-64, Epub 2011 Aug. 23.

52. Turin TC, Tonelli M, Manns BJ, Ravani P, Ahmed SB, Hemmelgarn BR,

Chronic Kidney disease and life expectancy. Nephrol Dial Transplant. Epub

ahead of print. Mar. 22, 2012.

53. Bosticardo G, Malberti F, Basile C, Leardini L, Libutti P, Filiberti O, Schillaci E,

Ravani P. Optimizing the dialysate calcium concentration in bicarbonate

hemodialysis. Nephrol Dial Transplant. 2012 Feb 21. Epub ahead of print.

54. Ravani P, Kilb B, Bedi H, Groeneveld S, Yilmaz S, Mustata S. The Duke

Activity Status Index in Patients with Chronic Kidney Disease: A Reliability

24

Study. Alberta Kidney Disease Network. Clin J Am Soc Nephrol. 2012 Feb.

16. Epub ahead of print.

55. Pecchini P, Malberti F, Mieth M, Quinn R, Tripepi G, Mallamaci F, Maas R,

Zoccali C, Ravani P. Measuring asymmetric dimethylarginine (ADMA) in

CKD: a comparison between enzyme-linked immunosorbent assay and liquid

chromatography-electrospray tandem mass spectrometry. J Nephrol. 2012

Feb 7:0. Doi:10.5301/jn.50000085. Epub ahead of print.

2011

56. Ronksley PE, Tonelli M, Quan H, Manns BJ, James MT, Clement FM, Samuel

S, Quinn RR, Ravani, P, Brar SS, Hemmelgarn BR. Validating a case

definition for chronic kidney disease using administrative data. Nephrol Dial

Transplant. Oct. 19, 2011.

57. Bruschi M, Carnevali ML, Murtas C, Candiano G, Petretto A, Prunotto M, Gatti

R, Argentiero L, Magistroni R, Garibotto G, Scholari F, Ravani P, Gesualdo L,

Allegri L, Ghiggeri GM. Direct characterization of target podocyte antigens

and auto antibodies in human membranous glomerulonephritits: Alfa enolase

and borderline antigents. J Proteomics 2011 Sept 6;74(10):2008-17. Epub

May 19, 201.

58. Murtas C, Ravani P, Ghiggeri GM. New insights into membranous

glomerulonephritis:from bench to bedside. Nephrol Dial Transplant. 2011

Aug;26(8):2428-30.

59. Carrero JJ, de Jager DJ, Verduijn M, Ravani P, DeMeester J, Heaf JG, Finne

P, Hoitsma AJ, Pascual J, Jarraya F, Reisaeter AV, Collart F, Dekker FW, Jager

KJ. Cardiovascualr and Noncardiovascular Mortality Among Men and Women

Starting Dialysis. Clin J Am Soc Nephrol. 20111 Jul;6(7):1722-30.

60. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E,

Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM.

Short term effects of rituximab in children with steroid and calcineurin

dependent nephrolotic syndrome: a randomized controlled trial. Clin J Am

Soc Nephrol. 2011 Jun;6(6):1308-15. Epub 2011 May 12. PMID: 21566104.

61. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men, CJ,

Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z,

Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S,

Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri

L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati

E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A,

Scolari F, Chen N, Zhang H, Lifton RP. Genome wide Association Study

Identifies Susceptibility Loci for IgA Nephrolopathy. Nat. Genet. 43(4) 321-

7). Apr 2011.

62. Clement FM, James MT, Chin R, Klarenbach SW, Mann BJ, Quinn RR, Ravani

P, Tonelli M, Hemmelgarn BR. Validation of a Case Definition to Define

25

Chronic Dialysis Using Outpatient Administrative Data. BMC Med Res.

Methodol:11:25. Mar 1, 2011.

63. Van de Luijtgaarden MW, Noordzij M, Stel VS, Ravani P, Jarraya F, Collart F,

Schon S, LEIVESTAD t, Puttinger H, Wanner C, Jager KJ. Effects of comorbid

and demographic factors on dialysis modality choice and related patient

survival in Europe. Nephrol Dial Transplant 10.1093. Feb 16, 2011.

64. James MT, Ghali WA, Knudtson ML, Ravani P, Tonelli M, Faris P, Pannu N,

Manns BJ, Klarenbach SW, Hemmelgarn BR. Associations between Acute

Kidney Injury and Cardiovascular and Renal Outcomes After Coronary

Angiography. Circulation. 123(4):409-416. Feb. 1, 2011.

65. Jones SM, Ravani P, Hemmelgarn BR, Muruve D, MacRae JM. Morphometric

and Biological Characterization of Biofilm in Tunneled Hemodialysis

Catheters. AM J Kidney Dis. Jan 21, 2011.

Year 2010

66. Giovanella L, Suriano S, Ricci R, Ravani P, Ceriani L. Circulating

procalcitonin in aseptic carcinoma patients: a specificity study with (18)F-

fluorodeoxyglucose positron-emission tomography/computed tomography as

benchmark. Clin Chem Lad Med. 2010 Aug;48(8)L1163-5.

67. Palmer SC, Navaneethan SD, Craig JC, Ravani P, et al. Meta-

analysis:erythropoiesis-stimulating agens in patients with chronic kidney

disease. Ann Intern Med. Jul 6 2010;153(1):23-33.

68. Limardo M, Imbasciati E, Ravani P, et al. Pregnancy and Progression of IgA

Nephropathy: Results of an Italian Multicenter Study. Am J Kidney Dis.

Jul 2 1010.

69. Ravani P, Parfrey P, MacRae J, et al. Modeling Survival of arteriovenous

accesses for hemodialysis: semiparametric versus parametric methods. Clin

J Am Soc Nephrol. Jul 2010;5(7):1243-1248.

70. Scolari F, Ravani P. Atheroembolic Renal Disease. The Lancet. Apr 9, 2010.

71. Hemmelgarn BR, Zhang J, Manns BJ, Ravani P, et al. Nephrology visits and

health care resource use before and after reporting estimated glomerular

filtration rate. JAMA. Mar 24 2010;303(12):1151-1158.

72. Quinn R, Ravani P, Hochman J. Technique failure in peritoneal dialysis

patients: insights and challenges. Perit Dial Int 30(2): 161-2. Mar 2010.

73. Ravani P, Gaggi R, Rollino C, et al. Lack of association between dialysis

modality and outcomes in atheroembolic renal disease. Clin J Am Soc

Nephrol. Mar 2010; 5(3):454-459.

Year 2009

74. Cianciaruso B, Pota A, Di Giuseppe D, Di Micco L, Pisani A, Bellizzi A, Minutolo

R, Sabbatini M, Ravani P. Impact of two different low protein diets on

26

survival of CKD patients (stage 4-5) Am J Kidney Dis, 2009 Dec;54(6):1052-

6.

75. Cianciaruso B, Pota A, Bellizzi V, Ravani P. Effect of a low versus moderate

protein diet on progression of CKD: Follow up of a randomized controlled

trial. Am J Kidney Dis. Dec 2009:54(6):1052-1061.

76. Hemmelgarn BR, Clement F, Manns BJ, Klarenbach S, James MT, Ravani P,

Pannu N, Ahmed SB, MacRae J, Scott-Douglas N, Jindal K, Quinn R, Culleton

BF, Wiebe N, Krause R, Thorlacius L, Tonelli M. Overview of the Alberta

Kidney Disease Network. BMC Nephrol: 2009 Oct 19;10:30.

77. Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G,

Innocenti ML, Somenzi D, Trivelli A, Caridi G, Allergri L, Ghiggeri GM. Renal

outcome in patients with congential anomalies of the kidney and urinary

tract. Kidney Int 2009 Sept; 76(6): 528-33.

78. James MT, Manns BJ, Hemmelgarn BR, Ravani P. For the Alberta Kidney

Disease Network: What's Next After Fistual First: Is an arteriovenous graft

or Central Venous Catheter Preferable when an Arteriovenous Fistual is not

Possible? Semin Dial 2009 Sept-Oct;22(5):539-44.

79. Caridi G, Gigante M, Ravani P. Clinical features and long-term outcome of

nephritic syndrome associated with heterozygous NPHS1and NPHS2

mutations. Clin J Am Soc Nephrol. Jun 2009;4(6):1065-1072.

80. Caridi G, Gigante M, Ravani P, Trivelli A, Barbano G, Scolari F, Dagnino M,

Murer L, Murtas C, Edefonti A, Allegri L, Amore A, Coppo R, Emma F, De Palo

T, Penza R, Gesualdo L, Ghiggeri GM. Clinical Features and Long-Term

Outcome of Nephrotic Syndrome Associated with Heterozygous NPHS1 and

NPHS2 Mutations. Clin J Am Soci Nephrol;2009 Jun;4(6):1065-72

81. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S,

Pollett WG. Concordance with clinical practice guidelines for adjuvant

chemotherapy in patients with Stage I-III colon cancer: experience in 2

Canadian provinces. Can J Surg, 2009 Apr; 52(2):92-7.

82. Ravani P, Malberti F, Tripepi G. Vitamin D levels and patient outcome in

chronic kidney disease. Kidney Int. Jan 2009;75(1):88-95.

83. Ravani P, Barrett B, Parfrey P. Modeling Longitudinal Data I: Principles of

Multivariate Analysis. Methods in Molecular Biology 2009;473;39-60

84. Pirulli D, Crovella S, Ulivi S, Zadro C, Bertok S, Rendine S, Scolari F,

Foramitti M, Ravani P. European IgAN Consortium: Genetic variant of

C1GA1T1 contributes to the susceptibility to IgA nephropathy. J Nephrol.

2009 Jan-Feb;22(1):152-9

85. Sanna-Cherchi S, Ravani P, Corbani V, Parodi S, Haupt R, Piaggio G, Degli

Innocenti M, Somenzi D, Trivelli A, Caridi G, Izzi C, Scolari F, Mattioli G,

Allegri L, Ghiggeri GM. Congenital Anomalies of the Kidney and Urinary Tract

(CAKUT): Longitudinal Cohort Study on Renal Outcome. Kidney Int, 2009,

Septl76(5):528-33.

27

86. Malberti F, Ravani P. Effect of Calcitriol (CT) and paricalcitol (P) on the PTH

(1-84)/large caroxy-terminal PTH fragments ratio in dialysis patients. WCN

2009, Milan, IT.

87. Ravani P, Barrett B, Parfrey P. Modeling Longitudinal Data II: Standard

Regression Models and Extensions. Methods Mol Biol. 2009:473:61-94

88. Parfrey P, Ravani P. On framing the research question and choosing the

appropriate research design. Methods Mol Biol 2009;473:1-17

89. Malberti F, Ravani P. Effect of Calcitriol and Paricalcitol on the PHT (1-84)

large carboxy-terminal PTH fragments ratio in dialysis Patients. ISN/EDTA,

2009.

Year 2008

90. Ravani P, Parfrey P, Gadag V, Malberti F, Barrett B. Clinical research of

kidney diseases V: extended analytic models. Nephrol Dial Transplant. 2008

May;23(5):1484-92.

91. Ravani P, Parfrey P, Dicks E, Barrett B. Clinical research of kidney disease

II: problems of study design. Nephrol Dial Transplant. Apr 9, 2008

92. Interdisciplinary Chronic Disease Collaboration (Ravani, P co-author). The

Research to health policy cycle: a tool for better management of chronic non-

communicable diseases. J. Nephrol 21;621-631, 2008

93. Ravani P, Parfrey P, Murphy S, Gadag V, Barrett B. Clinical Research of

Kidney Disease IV: Standard Regression Models. Nephrol Dial Transplant

2008;23(2)475-82.

94. Cianciaruso B, Ravani P, Barrett B, Levin A. Italian Randomized Trial of

Hemoglobin maintenance to Prevent or Delay Left Ventricular Hypertrophy in

Chronic Kidney Disease. JOF Nephrol 2008:21:861-870.

Year 2007

95. Ravani P, Parfrey PS, Curtis B, Barrett BJ. Clinical Research of Kidney

Diseases I:researchable questions and valid answers. Nephrol Dial

Transplant. Dec 2007:22(12):3681-3690

96. Ravani P, Parfrey PS, Dicks E, Barrett BJ. Clinical Research of Kidney

Disease II: Problems of study design. Nephrol Dial Transplant 2007,

Oct;22(10):2785-94.

97. Ravani P, Parfrey PS, Curtis B, Barrett BJ. Clinical Research of Kidney

Diseases I; researchable questions and valid answers. Nephrol Dial

Transplant 2007 Sep;22(9):2459--68

98. Scolari F, Ravani P, Gaggi R. The Challenge of diagnosing Atheroembolic

Renal Disease: Clinical Features and Prognostic Factors. Circulation: 2007

Jul 17;116(3):298-304

99. Imbasciate E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice

A, Ravani P. Pregnancy in CKD stages 3 to 5: Fetal and Maternal Outcomes.

Am J Kidney Dis, 2007;49; 753-762.

28

100. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C.

Urotensin II is an Inverse Predictor of Death and Cardiovascular Events in

Chronic Kidney Disease. Kidney Int. Jan 2007;73(1):95-101

101. Roy-Chaudhury P, Spergel LM, Besarab A, Asif A, Ravani P. Biology of

Arteriovenous Fistual Failure. J Nephrol, 2007:20:150-63.

102. Ravani P, Spergel LM, Asif A, Roy-Chaudhury P, Besarab A. Clinical

Epidemiology of Arteriovenous Fistula. 2007 J Nephrol:20:141-9.

103. Besarab A, Ravani P, Spergel L, Roy-Chaudhury P, Asif A. AVF in 2007:

Research Needs. J of Nephrology:20:668-73.

104. Asif A, Besarab a, Roy-Chaudhury P, Spergel LM, Ravani P. Interventional

Nephrology: From Episodic to Coordinated Vascular Access Care. J Nephrol

2007 Jul-Aug:20(4) 399-405.

105. Spergel LM, Ravani P, Roy-Chaudhury P, Asif A, Besarab A. Surgical

salvage of the Autogenous Arteriovenous Fistual. AVF. J Nephrol; 2007 Jul-

Aug:20(4):399-405.

106. Ravani P, Parfrey P, Gadag V, Malberti F, Barrett B. Clinical Research of

Kidney Diseases III: Principles of Regression and Modeling. Nephrol Dial

Transplant 2007: 22:3422-30

107. Ravani P, Malberti F. Confounding and interaction in the general linear

model. G Ital Nefrol 2007:24-60-65.

108. Ravani P, Del Vecchio L, De Nicola L, Cianciaruso B. Erythropoietins and

Haemoglobin targets to prevent the progression of Chronic Kidney Disease:

Guideling from the Italian Society of Nephrology. G Ital Nefrol;2007 Jan-Feb

24 Suppl 37:91-8.

109. Del Vecchio L, Manno C, Ravani P, De Nicola L, Cianciaruso B.

Antihypertensive agents for the prevention of Chronic Kidney Disease

Progression. Guideline from the Italian Society of Nephrology. G Ital Nefrol.

2007 Jan-Feb;24 suppl 37;64-82.

110. De Nicola L, Strippoli GF, Ravani P, Del Vecchio L, Cianciaruso B. Use of

statins for preventing cardiovascular and renal outcomes in patients with

Chronic Kidney Disease excluding dialysis: Guideline from the Italian Society

of Nephrology. G Ital Nefrol 2007 Jan-Feb; 24 Suppl 37:83-90. Italian

111. Spergel LM, Ravani P, Asif A, Roy-Chaudhury P, Besarab A. Autogenous

Arteriovenous Fistuala Options. J Nephrol, 2007 May-June 20(3):288-98.

112. Asif A, Ravani P, Roy-Chaudhury P, Spergel LM, Besarab A. Vascular

Mapping Techniques: Advantages and Disadvantages. J Nephrol 2007 May-

June:20(3)299-303.

113. Besarab A, Asif A, Roy-Chaudhury P, Spergel LM, Ravani P. The Native

Arteriovenous Fitsual in 2007. Surveillance and monitoring. Nephrol. Nov-

Dec 2007;20(6):656-667.

29

114. Besarab A, Ravani P, Spergel LM, Roy-Chaudhury P, Asif A. The Native

Arteriovenous Fistuala in 2007. Research needs. J Nephrol. Nov-Dec 20(6):

668-673.

Year 2006

115. Ravani P, Andrulli S. Reporting and Interpreting the Result of a Clinical

Study (P value and confidence intervals). G Ital Nefrol. 2006 Sept-

Oct;23(5):490-501. Italian Review

116. Dicks EL, Ravani P, Langman DS, Davidson WS, Pei Y, Parfrey PS. Incident

Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney

Disease: A population and family based cohort followed for 22 years. Clin J

Am Soc Nephrol 1: 2006; 710-717.

117. Ravani P, Malberti F. More infiltrations in less mature fistula: Am J Kidney

Dis. 2006 48:181.

118. Izzi C, Ravani P, Torres D, Prati E, Viola BF, Guerini S, Foramitti M, Frasca

G, Amoroso A, Ghiggeri GM, Schena FP, Scolari F. IgA Nepropathy: the

presence of familial disease does not confer an increased risk of progression.

Am J Kidney Dis 47:761-769, 2006.

119. Mandolfo S, Borlandelli S, Ravani P, Imbasciati E. How to improve dialysis

adequacy in patients with vascular access problems. J Vasec Access;2006

7:53-9.

120. Ravani P, Andrulli S. (Clinical relevance of study results). G Ital Nefrol. 2006

23:163-72. Italian.

121. Ravani P, Malberti F. More infiltrations in less mature fistula? Am J Kidney

Dis. 2006 48:181.

Year 2005

122. Ravani P, Strippoli G. Update on Renal Anaemia Management. Hospital

Pharmacy Europe. Nov-Dec 2005.

123. Ravani P, Malberti F, Tripepi G, Testa S, Mallamaci F, Zoccali C.

Asymmetrical DiMethyl-Arginine(ADMA) predicts progression to dialysis and

death in patiens with Chronic Kidney Disease (CKD): A competing risks

modeling approach. J Am Soc Nephrol. 2005 Aug:16(8):2449-55. Epub 2005

June 8.

124. Ravani P, Malberti F. NNT for studies with long-term follow up: keep it

simpler but not too simple. Ecmaj, 11 April 2005

http://www.cmaj.ca/cgi/eletters/172/5/613-a#2332.

125. Ravani P, Barrett B, Mandolfo S, Brunori G, Cancarini G, Imbasciati E,

Malberti F. Factors associated with unsuccessful utilization and early failure

of the arteriovenous fistula for hemodialysis. J Nephrol 2005 March-

April;18(2): 188-96.

126. Copercinic B, Ravani P, Malberti F. Acute renal failure after right

nephrectomy for spontaneous rupture and left renal vein ligature. Clin

Nephrol. 2005 Aug;64(2):167-70.

30

127. Sreenarasimhaiah V, Ravani P. Arteriovenous fistula surgery: An American

perspective from Italy. Semin dial. 2005, Nov-Dec;18(6):542-9.

128. Malberti F, Ravani P. Control of calcium and phosphate metabolism

derangements and prevention of vascular calcifications in dialysis patients. G

Ital nefrol. 2005 Jan-Feb 22 Suppl 31:S47-52.

129. Brunori G, Ravani P, Mandolfo S, Imbasciati E, Malberti F, Cancarini G.

Fistual Maturation: doesn't time matter at all? Nephrol Dial Transplant. 2005

April;20(4):684-7.

130. Ravani P, Malberti F. Introduction to the general linear models. G Ital

Nefrol(5):490-3 Italian. (Sept-Oct 22 2005).

131. Ravani P, Malberti F. Statistical models and multivariable analysis. G Ital

Nefrol. 2005 Jul-Aug;22(4):348-53 review Italian.

Year 2004

132. Ravani P, Brunori G, Mandolfo S, Cancarini G, Imbasciati E, Marcelli D,

Malberti F. Cardiovascular comorbidity and late referral impact arteriovenous

fistula survival a prospective multicenter study. J Am Soc Nephrol. 15:204-9;

Jan 1, 2004.

133. Curtis BM, Ravani P, Malberti F, Kennett F, Taylor PA, Djurdjev O, Levin A.

The short and long term impact of multi-disciplinary clinics in addition to

standard nephrology care on patient outcomes. Nephrol Dial Transplant

2004 Dec 7; (Epub ahead of pring)doi:10.1093/ndt/gfh585.

134. Malberti F, Ravani P. Disturbances of mineral metabolism and vascular

calcifications in dialysis patients. G Ital nefrol. 2004 May-June; 21(3):238-

44.

Year 2003

135. Malberti F, Ravani P. The choice of the dialysate calcium concentration in

the management of patients on hemodialysis and hemodiafiltration. Nephrol

Dial Transplant 18 (Suppl 7:37-s40). Aug 2003.

136. Ravani P, Marcelli D, Malberti F. In reply. Am J Kidney Dis. 2003 May:

41(5):11:27.

137. Malberti F, Ravani P. Effect of an ambulatory program devoted to chronic

renal insufficiency on the reduction of mobidity and hospitalization among

patients at the beginning of dialysis treatment. G Ital Nefrol 20(2):127-32.

Mar 2003.

138. Scolari F, Ravani P. Pola A, Guerini S, Zubani R, Movilli E, Savoldi S,

Malberti F, Maiorca R. Predictors of renal and patient outcomes in

atheroembolic renal disease: A prospective study. J Am Soc Nephrol

14:1584-90. 2003.

139. Ravani P, Marinangeli GC, Stacchiotti L, Malberti F. Structured pre dialysis

programs: More than just timely referral? J Nephrol 16:862-869. 2003.

31

140. Ravani P, Mariinangeli GC, Trancredi M, Malberti F. Multidisciplinary chronic

kidney disease management improves survival on dialysis. J Nephrol 16:870-

877. 2003.

141. Conte F, Ravani P, Baragetti I, Lagona C, Malberti F, Marchesi D, Ogliari V,

Paris V, Porri MT, Rossi B, Ballerini L. Pre Dialysis Education Programs and

Early Dialysis Outcomes: A multi center study. J Am Soc Nephrol 14:246A.

2003.

Year 2002

142. Ravani P, Marcelli D, Malberti F. Vascular Access Surgery Managed by Renal

Physicians: The Choice of Native Arteriovenous Fistulas for Hemodialysis.

Am J Kidney Dis 40:1264-1276. Dec 2002.

Year 2001

143. Mandolfo S, Galli F, Costa S, Ravani P, Gaggi P, Imbasciati E. Factors

influencing permanent catheter performance. The J of Vascular Access, vol

2, n3:106-109. Sep 2001.

144. Ravani P, Marcelli D, Pecchini P, Malberti F. Early Failure rates of

Arteriovenous Fistulas for hemodialysis: Evaluation of six year activity. J Vasc

Access 2: 154-160. 2001.

Year 2000

145. Mandolfo S, Bucci , Ravani P, Imbasciati E. Dialysis prescription in elderly

hemodialysis patients. The J of Vasculal Access. Vol. 1n.4:139-143.

Dec.2000.

ii. Books; Chapters Peer Reviewed

1. Ravani P. Toxic Nephropathies: Nonsteroidal Anti-inflammatory

Drugs;(chapter 27). Evidence Based Nephrology. Edited by GFM

Strippoli;2010.

2. Ravani P. Toxic Nephropathies: Environmental Agents and Metals; (chapter

28). Evidence Based Nephrology; Edited by GFM Strippoli; 2010.

3. Ravani P. The Kidney in pregnancy; (chapter 29). Evidence Based

Nephrology; Edited by GFM Strippoli; 2010.

4. Parfrey P, Ravani P. On Framing the Research Question and Choosing the

Appropriate Research Design. Methods in Molecular Biology; 2009.

5. Ravani P, Barrett BJ, Parfrey PS. Modeling Longitudunal Data II. Standard

Regression Models and Extensions in "Methods in Molecular Biol"., Edited by

P.S. Parfrey "Methods in Molecular Medicine" . 2009:473:61-94.

6. Ravani P, Barrett BJ, Parfrey PS. Modeling Longitudunal Data I: Principles

of Multivariate Analysis. Methods Molecular Medicine. Edited by P.S.

Parfrey: 2009;473:39-60.

7. Ravani P, Parfrey PS. Cardiovascular Disease in Chronic Kidney Disease.

"Suki & Masry's Therapy of Renal Diseases and Related Disorders", Fourth

Edition;2007.

32

iii. Abstracts-Published Peer Reviewed

1. Leung K, Chowdhury T, Ma Z, Parker K, Tang N, Wytsma K, Mustata S,

Ravani P, Quinn R, MacRae J: Exercise training during hemodialysis is not

associated with Intra-dialytic hypotension. CSN 2014; Vancouver

2. Kabani R, Quinn R, Palmer S, Lewin A, Yilmaz S, Tibbles LA, Lorenzetti D,

Strippoli G, McLaughlin K, Ravani P. Risk of Death following Kidney Allograft

Failure: A Systematic Review and Meta-analysis of Cohort Studies. CSN

2014; Vancouver.

3. Chin-Lenn L, Cherniak W, Mack L, Temple W, Quinn R, Ravani P, Lewin A,

Quan ML. Predictors of treatment with mastectomy, use of sentinel lymph

node biopsy and upstaging to invasive cancer in patients diagnosed with

DCIS on core biopsy. American Society of Breast Surgeons 14th Annual

Meeting. May 1, 2013.

4. Leung K, Quinn R, MacRae J, Strippoli G, Oliver M, Tai D, James M, Ravani

P. Association between type of hemodialysis access and risk of infections:

systematic review. CSN 2013; Montreal.

5. Ravani P, Ghiggeri GM. Use of Rituximab in Children with Steroid and

Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome. CSN 2013;

Montreal.

6. Dulai M, Ravani P, Oliver MJ, MacRae J, Quinn R. Willingness of physicians

to participate in a randomized trial comparing different forms of Vascular

Access. CSN 2013; Montreal.

7. Ma J, Heyland J, Hemmelgarn B, Ravani P, Pannu N, Knudtson M, James MT.

Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and

Risk of Contrast Induced Acute Kidney Injury: Systematic Review and Meta-

analysis. CSN 2013; Montreal.

8. James MT, Karsanji D, Quinn R, Ravani P, Hemmelgarn BR, Pannu N, Manns

BJ. Nephrologist's Opinions on outpatient follow up after hospitalization with

Acute Kidney Injury. CSN 2013; Montreal.

9. Ravani P, Oliver M, Quinn R, MacRae J, Tai D, Thomas C, Pannu N, Tonelli

M, Hemmelgarn BR, Manns BJ, Palmer S, Strippoli G, James M. Vascular

Access type and mortality in people on hemodialysis: systematic review.

CSN 2012; St. John's, NF & LB.

10. Ravani P, Oliver M, Quinn R, MacRae J, Tai D, Thomas C, Pannu N, Tonelli

M, Hemmelgarn BR, Manns BJ, Palmer S, Strippoli G, James M.

Access type and mortality in people on hemodialysis: systematic review.

EDTA 2012; Paris.

11. Ravani P, Palmer S, Oliver JM, Quinn R, MacRae J, Tai D, Thomas C, Pannu

N, Hemmelgarn BR, Craig J, Manns BJ, Tonelli M, Strippoli G, James MT.

Association between type of hemodialysis access and clinical outcomes:

Meta analysis of cohort studies. ASN 2012; San Diego.

33

12. Ravani P, Gillespie B, Quinn R, MacRae J, Manns BJ, Mendelssohn D, Tonelli

M, Hemmelgarn BR, James M, Pannu N, Zhang X, Pisoni R. Risk of Infectious

and Non-Infectuous Complications of Permanent Hemodialysis Access. ASN

2012; San Diego.

13. Wong B, Ravani P, Manns BJ, Zhang X, Chin R, Hemmelgarn BR, Tonelli M,

Oliver M, Quinn R. Increasing Erythropoiesis Stimulating Agent Dosage in

Hospitalized Patients Increases Risk of Overshooting Traget Hemoglobin and

Does Not Reduce Transfusion Risk. ASN 2012; San Diego.

14. Wong B, Ravani P, Manns BJ, Zhang X, Chin R, Hemmelgarn BR, Tonelli M,

Oliver M, Quinn R. Patterns and Predictors of Blood Transfusion among

Hospitalized Hemodialysis Patients. ASN 2012; San Diego.

15. Elliott M, James M, Palacios-Derflingher L, Tonelli M, Manns BJ, Quinn R,

Ravani P, Kline G, Hemmelgarn BR. Bisphosphonate Use in Chronic Kidney

Disease. ASN 2012; San Diego.

16. Manns BJ, Scott-Douglas N, Klarenbach S, Moist L, Tonelli M, Ravani P, Au

F, Dorval M, Lok C, Chui B, Wiebe N, Hemmelgarn BR. A Comparison of

costs of Using Once Weekly rt-PA or Heparin as a Locking Solution for

Hemodialysis Catheters: Findings from the Prevention of Catheter Lumen

Occlusion with rt-PA versus Heparin (pre-clot) Randomized Trial. ASN 2012;

San Diego.

17. Ravani P, Malberti F, Pirelli S, Scolari F, Barrett B. Randomized Controlled

Trial of Bicarbonate versus Saline Infusion Therapy to Prevent Contrast

Induced Nephropathy. Can it prevent- ERA/EDTA; 2011: Rrague.

18. Pecchini P, Mieth M, Maas R, Tripepi G, Malberti F, Mallamaci F, Quinn R,

Zoccali C, Ravani P. Validation of an ELISA for the measurement of Plasma

Asymmetric Di-Methyl Arginine in patients with Chronic Kidney Disease.

EDTA 2011; Prague.

19. Ravani P, Pecchini P, Quinn R, Mallamaci F, Tripepi G, Malberti F, Mieth M,

Maas R, Zoccali C. Homo-arginine is an Inverse Predictor of Mortality in

Patients with Chronic Kidney Disease. EDTA 2011; Prague.

20. Ravani P, Pecchini P, Mieth M, Maas R, Tripepi G, Malberti F, Zoccali C.

Validation of an ELISA for the measurement of plasma ADMA in patients with

CKD. WCN 2011; Vancouver.

21. Wong BC, Chin R, Hemmelgarn BR, Ravani P, Quinn R. Patterns and

Predictors of Blood Transfusion among Hospitalized Hemodialysis Patients.

ASN 2011; Vancouver.

22. Limardo M, Imbasciati E, Ravani P. Gravidanza e progression della

nefropatia a depositi IgA: risultati di uno studio Multicentrico Italiano.

SIN 2010.

34

23. Ravani P, Parfrey P, MacRae J, James M, Quinn R, Malberti F, Brunori G,

Mandolfo S, Tonelli M, Hemmelgarn BR, Manns BJ, Barrett B. How to model

survival of Arteriovenous Accesses for Hemodialysis: semi-parametric or

parametric methods? ERA-EDTA Annual Meeting. 2010; Munich.

24. Ravani P, Parfray P, MacRae J, James M, Quinn R, Malberti F, Brunori G,

Mandolfo S, Tonelli M, Hemmelgarn BR, Manns BJ, Barrett B.

How to model survival of Arteriovenous Accesses for Hemodialysis: semi-

parametric or parametric methods? CSN Annual Meeting 2010; Montreal.

25. Ravani P, Pecchini P, Tripepi G, Mallamaci F, Zoccali C, Malberti F. Vitabin D

Levels and Patient Outcomes in Chronic Kidney Disease: A Longitudinal

Cohort Study. EDTA :2009.

26. Limardo M, Pozzi C, Imbasciati E, Surian M, Torres D, Beati S, Gregorini G,

Magistoni R, Basellato D, Ravani P, Ambroso G. Kidney and Pregnancy

Study Group of the Italian Society of Neprholgoy: Does Pregnancy Influence

the long term outcome of IgA Nephrology? Results of a multicentre

retrospective observational study. WCN: 2009.

27. Kilb B, Ravani P, Groenveld S, Yilmaz D, Mustata S. Screening

Cardiopulmonary Fitness in Patients with Chronic Kidney Disease. ASN; Oct

2009;San Diego.

28. Mandolfo S, Ravani P, Bucc R, Corradi B, Farina M, Barbisoni F, Elli A. A

studio crossover per valutare il ruolo dei filtri con Vitamina E sull'anemia nei

pazenti in emodialisi con catetere venoso central. SIN 2009.

29. Malberti F, Ravani P. Effetto del calcitriolo e del paracalcitolo sul rapport

PTH (1-84)/frammenti C-Terminali nei pazienti in dialisi. SIN 2009.

30. Hemmelgarn BR, Zhang J, Manns BJ, Tonelli M, Karenbach S, Culleton B,

Krause R, Thorlacius L, Ravani P. Impact of Estimated GFR Reporting on

Rate of New Nephrology Visits. WCN 2009;Milan, IT.

31. Cornacchia F, Malberti F, Villa M, Lucchi S, Mannino S, Ravani P. Creatine

based equations in mildly impaired or normal Kidney Function. Cremona

Study; ERA-EDTA: 2008; Stockholm, Sweden.

32. Scolari F, Ravani P, Gaggi R, Rollino C, Santostefano M, Colla L, Valerio F,

Dallera N, Viola BF. Patient and renal outcomes in Atheroembolic Renal

Disease (AERD): Impact of dialysis modality. ERA-EDTA: 2008; Stockholm,

Sweden.

33. Ravani P, Pecchini P, Tripepi G, Mallamaci F, Malberti F, Zoccali C. Vitamin D

levels and mortality among Chronic Kidney Disease (CKD)patients. ERA-

EDTA; 2008; Stockholm, Sweden.

34. Pontoriero G, Conte F, Corghi E, Limido A, Malberti F, Spotti D, Ravani P.

Use of catheters in incident hemodialysis (HD) patients. ERA-EDTA; 2008:

Stockholm, Sweden.

35

35. Malberti F, Conte F, Limido A, Spotti D, Pontoriero G, Corghi E, Ravani P.

Mortality rate in incident dialysis patients in the last two decades.

EDTA;2008.

36. Cornacchia F, Malberti F, Villa M, Lucchi S, Mannino S, Ravani P. Valore

Prognostico Delle Equazion Di Cockroft-Gault Ed MDRD in Soggetti Con

Funzione Renale Moderamente compromessa O Normale: Studio Cremona

(Creatinine-Based Equations in mildly impaired or normal Kidney function)

SIN 2008.

37. Pecchini P, Ravani P, Tripepi G, Mallamaci F, Malberti F, Zoccali C. Livelli Di

Vitamina D e Outcomes Del Paziente Nell' Insufficienza renale Cronica. SIN

2008.

38. Pontoriero G, Conte F, Corghi E, Limido A, Malberti F, Spotti D, Ravani P.

Utilizzo DI Catereri Nei Paziente Incidenti in Dialisi. SIN 2008.

39. Malberti F, Conte F, Limido A, Spotti D, Pontoriero G, Corghi E, Ravani P.

Mortalita' nei pazienti incidenti in dialisi negli ultimo due decennia. SIN

2008.

40. Scolari F, Ravani P, Gaggi R, Rollino C, Santostefano M, Colla L, Valerio F,

Dallera N, Viola BF. Outcomes renale e del paziente nella malattia

ateroembolica renale: Impatto del tipo de dialisi. SIN 2008.

41. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C.

L'Urotensin II e' un predittore inverso di mortalita' generale e cardiovasculare

in pazienti affetti da malattia renale cronica in fase pre-dialitica. SIN

Meeting;Bari, IT;2008.

42. Besarab A, Asif A, Roy-Chaudhury P, Spergel LM, Ravani P. AVF in 2007:

Surveillance and Monitoring. J of Nephrology; 2007; 20:656-67.

43. Viola B, Ravani P, Gaggi R, Santostefano M, Rollino C, Scolari F. La diagnosi

clinica de malattia ateroembolica renale: Una sfida ma non necessariamente

"A needle in a Haystack" Risultati dello Studio Multicentrico Italiano. SIN

Meeting; 2007; Bari, IT.

44. Ravani P. Problemi Metodologici degli studi dell' insufficienza renale acuta

(invited lecture) SIN 2007; Bari, IT.

45. Levin A, Djurdjev O, Ravani P, McMahon L. Meta-analysis of individual

patient data from randomized trials with Epoetin Alpha Therapy; Progression

of Kidney Disease. SCN Meeting; Halifax 2007.

46. Scolari F, Ravani P. Clinical Diagnosis of Atheroembolic Renal Disease:

Challenging but not necessarily a "Needle in a Haystack". ISN Meeting; Rio

de Janeiro: 2007.

47. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C.

Urotensin II is an Inverse Predictor of Death from all Causes and

Cardiovascular Events in Chronic Kidney Disease State 2-5. EDTA Meeting;

Barcellona, IT: 2007.

36

48. Ravani P, Tripepi G, Pecchini P, Mallamaci F, Malberti F, Zoccali C.

L'Urotensin II e' un predittore inverso di mortalita' generale e cardiovasculare

in pazienti affetti da malattia renale cronica in fase pre-dialitica. SIN

Meeting;Bari, IT;2007.

49. Cremaschi E, Cavazzini S, Alinovi R, Paolo G, Parenti E, Ravani P,

Fiaccardori E, Cabassi A. Effects of Renal or Systemic Sympathectomy on

Angiotensis II-Mediated Renal Fibrosis in Rats. ASN; San Francisco, CA:

2007.

50. Scolari F, Gaggi R, Santostefano M, Rollino C, Ravani P. The Challenge of

Diagnosing Atheroembolic Renal Disease: Clinical Features and Prognostic

Factors. ASN;2007.

51. Levin A, Djurdjev O, Ravani P, McMahon L. Meta-analysis of individual

patient data from randomized trials with Epoetin Alpha Therapy; Progression

of Kidney Disease. ASN; 2007.

52. Imbasciati E, Ravani P, Gregorini G, Gammaro L, Cabiddu GF, Ambroso G,

Del Giudice A. La Granvidanza nelle donne con insufficienza renale cronica

moderata e severa:Fattori predittivi del rishio materno e fetale. SIN

Meeting; Bari, Italy; 2007.

53. Malberti F, Villa G, Colussi G, Quartagno R, Conte F, Farina M, Limido A,

Ravani P, Montagna G, Vezzoli G. II cinacalcet nella terapia

dell'iperparatisoidismo secondario non responsive alla terapia tradzionale.

SIN; 2006.

54. Ravani P, Barrett B, Gadag V, Malberti F. How to analyze survival data

where multiple events may occur within the same subject. A Nephrology

perspective. CSN; 2006.

55. Ravani P, Barrett B, Gadag V, Malberti F. How to analyze survival data

where multiple events may occur within the same subject. A Nephrology

perspective. EDTA; 2006.

56. Ravani P, Pechini P, Ghiringhelli P, Malberti F. Multidisciplinary Clinic and

Dialysis Outcomes: The Barrier of Late Patient Referral. Perit Dial Int 25

(suppl.5):S30.2005.

57. Ravani P, Malberti F, Test S, Tripepi G, Cutrupi S, Pizzini P, Mallamaci F,

Zoccali, C. II rischio di progrressione delle nefropatie croniche e

mortalita:ruolodell' Asymmetrical DI-Methyl-Arginine (adma). Ital Nefrol S-

32: S17; 2005.

58. Viola BF, Ravani P, Torres D, Izzi C, Prati E, Guerini S, Foramitti M, Sottini L,

Frasca G, Ghiggeri GM, Amoroso A, Schena FP, Scholari F. II fenotipo renale

non e diverso nelle forme famigliari e sporadiche di nefropatia a deposit IgA

(IgAN). G Ital Nefrol S-32:S9.2005.

59. Malberti F, Pecchini P, Ghiringhelli, Ravani P, Conte F. Efficacia del

cinacalcet nella terapia dell' iperparatiroidismo (IP) secondario non respnsivo

al calcitriolo ad alte dosi. G Ital Nefrol S-32: S47: 2005.

37

60. Ravani P, Malberti F, Testa S, Cutrupi S, Pizzini P, Tripepi G, Mallamaci F,

Zoccali C. Asymmetrical Di-Methyl-Arginine (ADMA) predicts progression to

dialysis and death in patients with Chronic Kidney Disease (CKD).

EDTA: 2005.

61. Maffei C, Ravani P, Scolari F. Insufficienza renale acuta e o subacuta

richiedente dialisi in corso di malattia ateroembolica renale Impatto sulla

sopravvivenza del paziente e del rene. GIN suppl. Giugno, 2004,

62. Ravani P, Madolfo S, Brunori G, Cancarini G, Imbasciati E, Malberti F.

Fattori che influenzano I risultati a brevet ermine della fistula arterovensoa

per emodialisi: Uno studio prospettico e multi-centrico. GIN supp. Giugno,

2004.

63. Ravani P, Brunori G, Mandolfo S, Cancarini G, Imbasciati E, Malberti F. Late

Referral and Cardiovascular Diseases Predict Worse Short-term Outcomes of

the Arteriovenous Fistula for Hemodialysis. A multicenter prospective study.

Nephrol Dial Transplant MP394:2004.

64. Mandolfo S, Ravani P, Cosci P, Curioni S, Barbisoni F, Corradi B, Farina M,

Bucci R, Malberti F, Imbasciati E. Worsening Clinical Profiles of Incident

Dialysis Patients and Early Mortality. Nephrol Dial Transplant SP321;2004.

65. Ravani P, Mandolfo S, Brunori G, Cancarini G, Imbasciati E, Malberti F.

Unsuccessful Utilization and Early Failure of the Arteriovenous Fistula for

Hemodialysis. A Prospect Multicenter Study. J Am Soc Nephrol SA-

PO296;2004.

66. Cianciaruso B, Ravani P, Torraca S, Andreucci VE. ITA-7Study Group. Effect

of Anemia Correction with Epoietin (EPO) on Left Ventricular Mass (LVM) in

patients with Chronic Kidney Disease (CKD). A Multicenter Randomized

Controlled Trial. J Am Soc Nephrol SU-PO066;2004.

67. Brunori G, Ravani P, Mandolfo S, Movilli E, Guerini S, Malberti F, Imbasciati

E, Cancarini GC. Short Term Outcome of the First Arteiovenous Fistula (AVF)

in hemodialysis Patients; A multicenter experience. Nephrol Dial Transplant :

733A;2003.

68. Scolari F, Ravani P, Guerini S, Malberti F, Maiorca R. Predictors of Renal

and Patient Outcomes in Atheroembolic Renal Disease: A prospective study.

Nephrol Dial Transplant: 18, 621A; 2003.

69. Ravani P, Conca M, Malberti F. Pre-dialysis Specialist Care and Survival on

Dialysis: An Attempt to Correct for Lead Time Bias. Nephrol Dial Transplant:

18, 671; 2003.

70. Ravani P, Brunori G, Canarini GC, Mandolfo S, Imbasciati E, Marcelli D,

Malberti F. Longer Maturation Time Imporves Arteriovenous Fistula Survival:

A prospective multi-center study. Nephrol Dial Transplant: 732A; 2003.

71. Scolari F, Ravani P, Viola GB, Guerini S, Frasca G, Ghiggeri GM, Maiorca R.

II fenotipo renale non e diverso nelle forme familiar di IGA "linked" e "non-

linked" al cromosoma. 6q 22-23. G Ital Nefrol: S23, A90; 2003.

38

72. Ravani P, Scolari F, Zubani R, Guerini S, Malberti F, Maiorca R. Effetto

renoprotettivo delle statine nei pazienti con malattia renale ateroembolica

(MRA). G Ital Nefrol. S39, A151; 2003.

73. Malberti F, Ravani P. Effetto di un ambulatorio dedicato all'insufficienza

renale cronica sulla morbilita nei pazienti che iniziano dialisi. G Ital Nefrol:

S49, A184; 2003.

74. Ravani P, Conca M, Malberti F. Cure specialistiche pre-dialitiche e

sopravvivenza in dialist: un tentaivo di controllo del lead-time bias. G Ital

Nefrol: S64, A239; 2003.

75. Ravani P, Brunori G, Mandolfo S, Imbasciati E, Cancarini G, Malberti F.

Effetto del tempo di maturazione sulla soprovvivenza della fistula

arterovenosa:risultato di uno studio prospettico. G Ital Nefrol: S69, A259;

2003.

76. Mandolfo S, Ravani P, Brunori G, Malberti F, Cancarini G, Marcelli D, Cogliati

P, Imbasciati E. Fattori determinate ed implicazioni cliniche del tipo d'accesso

vascolare (AV) all'inizio del trattamento emodialitico (HD). G Ital Nefrol:

S72,A271; 2003.

77. Brunori G, Ravani P, Mandolfo S, Movilli E, Guerini S, Malberti F, Cancarini

G. Risultati a brevet ermine del primo accesso vascolare (AVF): studio

multicentrico. G Ital Nefrol: S90, A343; 2003.

78. Ravani P, Brunori G, Mandolfo S, Cancarini G, Imbasciati E, Marcelli D,

Malberti F. Quality of Pre-Dialysis Care and Arteriovenous Fistula Survival: A

prospective multicenter study. J Am Soc Nephrol 14:53A ; 2003

79. Scolari F, Ravani P, Maffei C. Predictors of Renal and Patient Outcomes in

Atheroembolic Renal Disease: A prospective study. J Am Soc Nephrol

14:510a ; 2003.

80. Pecchini P, Olivetti L, Rozzi G, Ravani P, Grazioli L, Malberti F. Renal

Doppler Sonography and Magnetic Resonance Angiography in the Screening

of Reno-Vascular Disease. J Am Soc Nephrol 14:515A ;2003.

81. Ravani P, Marcelli D, Ghiringhelli P, Pecchini P, Malberti F. II fallimento

precoce della fistula arterovenosa (FAV) incidenza e fattori predittivi. G Ital

Nefrol: S82, A306; 2002.

82. Malberti F, Bufano G, Pecchini P, Ravani P, Ginocchi E. Livelli di PTH intatto

e di PTH 7-84 nei pazienti in emodialisi. G Ital Nefrol: S18, A177; 2002.

83. Pecchini P, Ravani P, Malberti F. Ruolo dei parametric ecografici renali

nellenefropatie croniche G Ital Nefrol: S9, A36; 2002

84. Scolari F, Pola A, Ravani P, Zubani R, Ferri P, Viola BF, Mazzucchelli C,

Malberti F, Maiorca R. Malattia Renale Ateroembolica: fattori di rischio

associate con la mortalita renale e del paziente. G Ital Nefrol: S43. A154;

2002.

39

85. Malberti F, Bufano G, Pecchini P, Ravani P, Ginocchi E. Intact PTH and 7-

84pth fragments in hemodialysis patients. Nephrol Dial Transplant 17:31,

O104; 2002.

86. Ravani P, Marcelli D, Cogliati P, Malberti F. Evidence based Medicine for

Nephrologists: Presentation of software for an EMB approach to Clinical

Studies. Nephrol dial Transplant 17:116, M24; 2002.

87. Ravani P, Marcelli D, Ghiringhelli P, Pecchini P, Malberti F. Survival of

Arteriovenous Fistual For Hemodialysis: A Single Center Longitudinal Cohort

Study. Nephrol Dial Transplant 17:281, T33; 2002.

88. Ravani P, Marcelli D, Pecchini P, Ghiringhelli P, Malberti F. The wrist as the

site for vascular access at hemodialysis initiation: Short term outcome and

implications. Nephrol Dialy Transplant 17:283, T339; 2002.

89. Ravani P, Ghiringhelli P, Ballerini L, Paris V, Malberti F. Impact of a Chronic

Kidney Disease Program (CKD-P)on patterns and modalities of dialysis

(D)start: an evidence based approach. Nephrol Dialy Transplant 17:294,

T379; 2002.

90. Ravani P, Malberti F. How the Pre-D Educational Program impacts clinical

outcomes after dialysis start. Baxter Symposium at the EDTNA Annual

Meeting. The Hague 2002-EDTNA/ERCA Abstract Book; 2002. Oral

Communication.

91. Ravani P, Ghiringhelli P, Paris V, Ballerini L, Malberti F. Analysis of Pre-

Dialysis Patient Flow pattern changes after the Institution of a Chronic Kidney

Disease Program. (CKD-P) J Am Soc Nephrol: 13, 624A;2002.

92. Ravani P, Ghiringhelli P, Paris V, Ballerini L, Malberti F. Cost Analysis of

Timely Preparation to Dialysis (D): An Italian Single-Center Study. J Am Soc

Nephrol: 13, 615A; 2002

93. Ravani P, Cogliati P, Pecchini P, Marcelli D, Malberti F. Consequences of

Late Referral on Vascular Access (VA):Outcomes in Patients Beginning

Hemodialysis (HD); A SINGLE CENTER Prospective Study. J Am Soc Nephrol:

13, 229A; 2002.

94. Ravani P, Marcelli D, Ghiringhelli P, Cogliati P, Malberti F. The Follow up

before ESRD and Short Term Survival of the First Artero-venous Fistula (AVF)

in Patients Beginning Hemodialysis (HD): A Single Centre Experience. J Am

Soc Nephrol: 13, 408A: 2002.

95. Ravani P, Brunori G, Mandolfo S, Marcelli D, Cogliati P, Imbasciati E,

Cancarni G, Malberti F. Survival of the First Arterovenous Fitstula (AVF) in

Patients Starting Hemodialysis (HD): A Multicenter study. J Am Soc Nephrol:

13, 410A; 2002.

96. Mandolfo S, Ravani P, Brunori G, Marcelli D, Cogliati P, Imbasciati E,

Cancarini G, Malberti F. Factors Affecting the Type of Vascular Access (VA) at

the Beginning of Hemodialysis (HD): Consequences and Implications. J Am

Soc Nephrol: 13, 699A; 2002.

40

97. Brunori G, Ravani P, Mandolfo S, Marcelli D, Cogliati P, Imbasciati E,

Malberti F, Cancarini G. Short Term Outcomes of the First Arteriovenous

Fistula (AVF) In Patients Beginning Hemodialysis (HD): A multicenter

experience. J Am SDoc Nephrol: 13, 697A; 2002.

98. Ravani P, Truppia MR, Ghirincghelli P, La Russa A, Malberti F. L'accesso

vascolare nel paziente che inizia il trattamento emodialitico. G Ital Nefrol:

Abs congress; 2001.

99. Ravani P, Arisi M, Cogliati P, Malberti F. The Vascular Access in Patients

starting Hemodialysis a six year experience. JASN: 301A, 1545, 200; 2001.

100. Brunori G, Ravani P, Zubani R, Verzeletti F, Movilli E, Cancarini GC, Malberti

F, Maiorca R. Survival of the first Vascular Access: a Comparison between

Elderly (>65 years)and younger (<65 years) patients. JASN: 284A, 1456;

2001.

101. Mandolfo S, Galli F, Costa S, Ravani P, Imbasciati E. Hemodialysis Catheter

Concundrum: How do they Work? Experience from four dialysis units.

Nephrol Dial Transplant vol. 15, n.9 A 186 G Ital Nefrol: S18, A177; 2000.

102. Bufano G, Pecchini P, Ravani P, Morstabilini P, Denti N. Testa S. Oxidative

Damage and Trace Elements in Hemodialysis Patientsl G Ital Nefrol 15: 155-

159; 1998.

103. Ghiringhelli P, Ariano R, Ravani P, Pecchini F. Oral Essential Amminoacids

and Chetoanologs in CAPD Patients: Effects on Albuminemia. IX National

Congress of Peritoneal Dialysis; p 315-7; 1997.

104. Bufano G, Ravani P, Pecchini F: Prognostic value of Bioimpedence in Patient

on Chronic Hemodialysis. G Ital Nefrol 14: S9A 1997.

105. Bufano G, Pecchini P, Ravani P, Testa S, Denit N, Morstabilini P; Trace

Elements and Oxidative damage in Dialysis Patients. It J of Mineral Metab,

10sl, n2 (A17); 1996.

106. Romano C, Bufano G, Pecchini P, Ravani P. Opposite Effects of Calcitriol

Treatment on serum Osteocalcin and Parathyroid Hormone in Dialysis

Patients. Italian Journal of Mineral and Electrolyte Metabolism; vol. 9n.304,

pp.165-167; 1994.

107. Romano C, Bufano G, Pecchini P, Ravani P. Therapy of the Uremic

Hyoeroarathyroidism with high dose Calcitrol. Cremona Medical Society

Bullettin, n.1; 1994.

108. Romano C, Ravani P, Pecchini P. ARF in Letptospirosis, poster at the First

Int. Congr. In Dev. Countries. Singapore; 1994.

41

42

43

44

45

46